Company Encyclopedia
View More
name
Pennant
PNTG.US
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.
381.83 B
PNTG.USMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
B
Health Care ServicesIndustry
Industry Ranking15/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.87%B
    • Profit Margin3.15%C
    • Gross Margin20.16%D
  • Growth ScoreA
    • Revenue YoY29.89%A
    • Net Profit YoY26.24%B
    • Total Assets YoY16.53%A
    • Net Assets YoY83.16%A
  • Cash ScoreA
    • Cash Flow Margin3173.43%A
    • OCF YoY29.89%A
  • Operating ScoreA
    • Turnover1.21A
  • Debt ScoreC
    • Gearing Ratio54.48%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The Pennant Group Issues Amended Financial Statements for Acquired Amedisys Subsidiaries

    The Pennant Group Inc. has issued an amendment to its current report, providing audited abbreviated financial statements for the acquired Amedisys subsidiaries as of and for the year ended December 31, 2024. The amendment includes statements of revenue and direct expenses, assets acquired, and liabilities assumed, along with related notes, to comply with SEC requirements.

    Reuters·
    US
    PNTG
    -0.07%
    Reuters·
    US
    PNTG
    -0.07%

    Buy Rating for Pennant Group: Strong Growth Potential and Attractive Valuation

    William Blair analyst Ryan Daniels has initiated a Buy rating for Pennant Group (PNTG), citing its growth potential and attractive valuation. The company's decentralized operating model enhances care delivery, and its shares are undervalued compared to peers. Daniels, a 3-star analyst, highlights Pennant's resilience in the healthcare sector, making it a compelling investment. Another report also reiterated a Buy rating with a $33.00 price target.

    Tip Ranks·
    US
    PNTG
    -0.07%
    Tip Ranks·
    US
    PNTG
    -0.07%

    Will Medicare’s 2026 Rule Shift and Amedisys Integration Strengthen Pennant Group’s (PNTG) Narrative?

    Truist Securities upgraded The Pennant Group to a buy rating, citing strong operating trends, sector demand, and reduced reimbursement risk from a less restrictive 2026 Medicare home health rule. The integration of 54 Amedisys locations supports Pennant's operational outlook. Pennant's Q3 2025 results and 2025 revenue guidance highlight growth from acquisitions. However, investors should consider Pennant's reliance on government payers and potential policy shifts. Pennant projects $1.2 billion revenue and $59.3 million earnings by 2028, requiring 13.6% yearly revenue growth.

    Simplywall·
    US
    PNTG
    -0.07%
    US
    AMED
    0.00%
    Simplywall·
    US
    PNTG
    -0.07%
    US
    AMED
    0.00%

    Stocks making big moves yesterday: Lam Research, Sweetgreen, Applied Materials, Lattice Semiconductor, and The Pennant Group

    This article highlights several stocks that experienced significant positive movement yesterday, including Lam Research, Sweetgreen, Applied Materials, Lattice Semiconductor, and The Pennant Group. Each company saw a rise in stock value due to various factors such as analyst upgrades, price target increases, or company expansion announcements. The piece details the specific reasons behind each stock's performance, providing financial figures and analyst insights.

    TradingView·
    US
    PNTG
    -0.07%
    US
    LSCC
    +3.12%
    US
    AMAT
    +1.15%
    TradingView·
    US
    PNTG
    -0.07%
    US
    LSCC
    +3.12%
    US
    AMAT
    +1.15%

    BUZZ-Pennant Group jumps after Truist upgrades on growth outlook

    Pennant Group's shares rose 3.22% after Truist Securities upgraded the stock to "buy" from "hold," citing strong operating trends and reduced reimbursement risk due to favorable 2026 Medicare rules. The brokerage raised the price target to $34, indicating a 19.7% upside. Pennant's acquisition integration is progressing well, with margins expected to normalize. All brokerages rate the stock as "strong buy" or "buy," with a median price target of $35.

    Reuters·
    US
    PNTG
    -0.07%
    Reuters·
    US
    PNTG
    -0.07%
    © 2025 Longbridge｜Disclaimer